Lumida
/CRDF
⌘K
Cardiff Oncology Inc

Cardiff Oncology Inc

CRDF
$0.88USD+0.63%+0.01 today

MARKET CAP

60.2M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$5

AI Summary

Stalk
TrimMedium

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

  • Onvansertib achieved 64% ORR vs 33% control in CARTF004 trial
  • Pfizer Ignite partnership enhances trial execution efficiency
  • Negative profitability profile with weak margins and earnings yield
Full analysis →
Insider Trades3 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 14, 2026BuyCRDFMani MohindruChief Executive Officer34,364$1.46$60.2M-80.68%+6.02%$50.0K+58.18%Trim
Jun 18, 2026BuyCRDFMani MohindruChief Executive Officer24,703$1.21$60.2M-80.68%+6.02%$29.9KTrim
Dec 16, 2024BuyCRDFJames E. LevineChief Financial Officer7,716$4.76$60.2M-80.68%+6.02%$36.7K+4.11%Trim